Through this acquisition, Telix is integrating its in-house development and marketing of radiopharmaceuticals more closely with the production of key therapeutic radioisotopes. ITM supplies, amongst other things, lutetium-177 and is expanding its capacity for other isotopes such as actinium-225 and terbium-161. The company supplies customers in more than 65 countries and achieved a turnover of 273 million US dollars in 2025. In addition, Telix gains access to ITM’s clinical pipeline. This includes ITM 11 for the treatment of gastroenteropancreatic neuroendocrine tumours. The active substance has already completed a Phase 3 trial. The two companies thus complement each other both technologically and along the value chain, from isotope production through drug development to marketing. For the industry, the transaction underscores the growing importance of vertical integration in the radiopharmaceutical market. As the number of clinical programmes increases, it is not only drug candidates and regulatory approvals that are becoming bottlenecks. At the same time, reliable isotope sources, production capacities, logistics and international supply chains are becoming crucial. It is precisely this infrastructure that is increasingly becoming a strategic asset in its own right.
News from “Telix Pharmaceuticals Limited” dated 21 September 2026